Zura Bio FY2025 EPS Forecast Increased by Leerink Partnrs

Zura Bio Limited (NASDAQ:ZURA) – Investment analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for shares of Zura Bio in a research note issued on Wednesday, December 11th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings per share of ($0.64) for the year, up from their previous estimate of ($0.67). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio’s FY2026 earnings at ($0.57) EPS.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12).

Several other analysts have also commented on ZURA. Piper Sandler restated an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a report on Thursday, September 19th. Chardan Capital lowered their target price on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a research note on Monday, November 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research report on Wednesday. Finally, Leerink Partners assumed coverage on shares of Zura Bio in a research report on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price on the stock. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $15.80.

Zura Bio Stock Up 3.6 %

NASDAQ:ZURA opened at $2.28 on Friday. The company has a 50-day moving average price of $3.76 and a 200-day moving average price of $3.80. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35.

Insider Buying and Selling at Zura Bio

In other news, Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 22.10% of the stock is owned by company insiders.

Institutional Trading of Zura Bio

Several large investors have recently modified their holdings of ZURA. Barclays PLC boosted its position in Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock worth $260,000 after purchasing an additional 56,757 shares during the last quarter. Geode Capital Management LLC grew its position in Zura Bio by 70.6% during the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after buying an additional 377,545 shares during the period. Sphera Funds Management LTD. purchased a new stake in Zura Bio during the third quarter valued at approximately $2,999,000. State Street Corp raised its position in Zura Bio by 47.5% in the third quarter. State Street Corp now owns 395,059 shares of the company’s stock worth $1,604,000 after acquiring an additional 127,300 shares during the period. Finally, Braidwell LP bought a new stake in shares of Zura Bio during the 3rd quarter valued at $10,040,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.